Enhancing the transparency and accessibility of information on medication risks and benefits, enabling patients to make informed healthcare decisions
Stigma and discretion : For those worried about others seeing them inject, a daily pill is discreet
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
GLP-1RAs may have direct beneficial effects on oxidative stress because the cAMPPKA pathway evoked by GLP-1RAs inhibited the NAD(P)H oxidasederived oxidative stress generation [33, 34]
